全文获取类型
收费全文 | 10507篇 |
免费 | 517篇 |
国内免费 | 36篇 |
专业分类
耳鼻咽喉 | 177篇 |
儿科学 | 213篇 |
妇产科学 | 182篇 |
基础医学 | 1725篇 |
口腔科学 | 383篇 |
临床医学 | 842篇 |
内科学 | 2043篇 |
皮肤病学 | 186篇 |
神经病学 | 1032篇 |
特种医学 | 652篇 |
外国民族医学 | 1篇 |
外科学 | 1260篇 |
综合类 | 73篇 |
预防医学 | 445篇 |
眼科学 | 255篇 |
药学 | 1001篇 |
中国医学 | 64篇 |
肿瘤学 | 526篇 |
出版年
2021年 | 125篇 |
2020年 | 92篇 |
2019年 | 116篇 |
2018年 | 155篇 |
2017年 | 126篇 |
2016年 | 175篇 |
2015年 | 232篇 |
2014年 | 296篇 |
2013年 | 400篇 |
2012年 | 563篇 |
2011年 | 609篇 |
2010年 | 354篇 |
2009年 | 369篇 |
2008年 | 623篇 |
2007年 | 682篇 |
2006年 | 627篇 |
2005年 | 650篇 |
2004年 | 641篇 |
2003年 | 622篇 |
2002年 | 602篇 |
2001年 | 140篇 |
2000年 | 119篇 |
1999年 | 139篇 |
1998年 | 129篇 |
1997年 | 116篇 |
1996年 | 88篇 |
1995年 | 86篇 |
1994年 | 88篇 |
1993年 | 99篇 |
1992年 | 82篇 |
1991年 | 65篇 |
1990年 | 60篇 |
1989年 | 77篇 |
1988年 | 59篇 |
1987年 | 63篇 |
1986年 | 45篇 |
1985年 | 69篇 |
1984年 | 59篇 |
1983年 | 58篇 |
1982年 | 59篇 |
1981年 | 69篇 |
1980年 | 47篇 |
1979年 | 52篇 |
1978年 | 46篇 |
1977年 | 63篇 |
1976年 | 47篇 |
1975年 | 45篇 |
1974年 | 34篇 |
1973年 | 35篇 |
1963年 | 34篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Neil Ryan Johanna Wall Emma J Crosbie Mark Arends Tjalling Bosse Saimah Arif Asma Faruqi Ian Frayling Raji Ganesan Ye L Hock Raymond McMahon Ranjit Manchanda W Glenn McCluggage Pinias Mukonoweshuro Gerhard van Schalkwyk Lucy Side John H Smith Bruce Tanchel D Gareth Evans C Blake Gilks Naveena Singh 《Histopathology》2019,75(6):813-824
2.
Deissler Heidrun L. Lang Gerhard K. Lang Gabriele E. 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2019,257(1):83-94
Graefe's Archive for Clinical and Experimental Ophthalmology - Intravitreal injection of the VEGF-binding protein aflibercept is widely used to treat various ocular diseases. In vitro,... 相似文献
3.
Raffit Hassan MD Christine Alewine MD PhD Idrees Mian MD Anna Spreafico MD PhD Lillian L. Siu MD FRCPC Carlos Gomez-Roca MD Jean-Pierre Delord MD PhD Antoine Italiano MD PhD Ulrik Lassen MD PhD Jean-Charles Soria MD PhD Rastilav Bahleda MD Anish Thomas MBBS MD Seth M. Steinberg PhD Cody J. Peer PhD William D. Figg PharmD Gerhard Niederfellner PhD Valérie Méresse Naegelen MD Ira Pastan PhD 《Cancer》2020,126(22):4936-4947
4.
Hermann Einsele MD Hossein Borghaei DO Robert Z. Orlowski MD Marion Subklewe MD Gail J. Roboz MD Gerhard Zugmaier MD Peter Kufer MD Karim Iskander MD Hagop M. Kantarjian MD 《Cancer》2020,126(14):3192-3201
Immuno-oncology therapies engage the immune system to treat cancer. BiTE (bispecific T-cell engager) technology is a targeted immuno-oncology platform that connects patients' own T cells to malignant cells. The modular nature of BiTE technology facilitates the generation of molecules against tumor-specific antigens, allowing off-the-shelf immuno-oncotherapy. Blinatumomab was the first approved canonical BiTE molecule and targets CD19 surface antigens on B cells, making blinatumomab largely independent of genetic alterations or intracellular escape mechanisms. Additional BiTE molecules in development target other hematologic malignancies (eg, multiple myeloma, acute myeloid leukemia, and B-cell non-Hodgkin lymphoma) and solid tumors (eg, prostate cancer, glioblastoma, gastric cancer, and small-cell lung cancer). BiTE molecules with an extended half-life relative to the canonical BiTE molecules are also being developed. Advances in immuno-oncology made with BiTE technology could substantially improve the treatment of hematologic and solid tumors and offer enhanced activity in combination with other treatments. 相似文献
5.
Christer Lunde Gjerstad Hans Jakob Bøe Erik Falkum Egil Wilhelm Martinsen Andreas Espetvedt Nordstrand Arnfinn Tønnesen Jon Gerhard Reichelt June Ullevoldsæter Lystad 《Journal of traumatic stress》2020,33(5):762-772
Peacekeeping missions involve experiences that may impact the mental health of participating soldiers. However, research on the long-term mental health consequences of peacekeeping is sparse. The present study aimed to find the prevalence of mental health problems (MHPs), possible MHP predictors, and associations between predictors and MHPs in Norwegian peacekeepers 18–38 years after deployment to a United Nations peacekeeping mission. We used data from a cross-sectional, postdeployment survey of Norwegian peacekeepers who served in Lebanon between 1978 and 1998 (N = 10,605). Participants were assessed for posttraumatic stress disorder (PTSD); anxiety; depression; insomnia; alcohol misuse; drug misuse; and exposure to pre-, peri-, and postdeployment stressors. Logistic regressions were executed to explore key variables associated with MHPs. Total MHP prevalence was 15.1%, 95% CI [14.4, 15.8]. The estimates for specific disorders were 0.1% for drug misuse, 3.4% for alcohol misuse, 4.0% for depression, 6.2% for PTSD, 6.4% for anxiety, and 9.3% for insomnia. Postdeployment stressors, OR = 1.91, 95% CI [1.79, 2.04]; employment status, OR = 1.41, 95% CI [1.33, 1.48]; and traumatic exposure during deployment, OR = 1.11, 95% CI [1.09, 1.12], were positively related to PTSD, χ2(17, N = 8,568) = 1,791.299, p < .001. Similar patterns were found for the other MHPs. Considering that most participants (84.9%) reported low symptom levels, our findings challenge the widespread public perception that most peacekeepers have MHPs. Moreover, our results indicate that future peacekeepers should be prepared for challenges they may face not only during deployment but also in the years following their homecoming. 相似文献
6.
7.
8.
9.
10.